Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

Is there a role for chronic suppressive therapy in herpes simplex virus infection?

Sandhya R. Nagarakanti, MD, FIDSA and Ahmed M. Zikri, PharmD
Cleveland Clinic Journal of Medicine March 2024, 91 (3) 151-153; DOI: https://doi.org/10.3949/ccjm.91a.23099
Sandhya R. Nagarakanti
Senior Associate Consultant, Division of Infectious Diseases, Mayo Clinic, Phoenix, AZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Ahmed M. Zikri
Clinical Specialist Pharmacist—Infectious Diseases and Antimicrobial Stewardship, Department of Pharmacy Services, Mayo Clinic, Phoenix, AZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Yes. The primary role of chronic suppressive therapy in herpes simplex virus (HSV) infection is to decrease the frequency, severity, and duration of outbreaks, and to reduce the risk of transmitting the virus to others. It is indicated in patients with recurrent oral and genital HSV-2 infection and oral HSV-1 infection. However, there is no clear proven benefit in providing chronic suppressive therapy in recurrent genital HSV-1 infection.

WHAT IS HSV INFECTION?

HSV infection is caused by 1 of 2 types of herpes viruses: HSV-1 and HSV-2. HSV-1 primarily causes oral herpes but can also cause genital herpes. It typically manifests as cold sores or fever blisters around the mouth. Transmission usually occurs through direct contact such as kissing, or by sharing items like utensils, cosmetics, or towels. In recent years, due to changes in sexual practices, HSV-1 has been causing an increasing number of genital herpes cases.1 HSV-2 is mainly responsible for genital herpes, resulting in sores or blisters on or around the genitals or rectum. It is mainly transmitted through sexual contact.

The initial episode of HSV infection can be categorized as either primary (ie, in patients without existing antibodies) or nonprimary (in patients with preexisting antibodies to the virus). Symptoms such as painful sores, fever, body aches, swollen lymph nodes, and headaches are more pronounced in primary infection than in non-primary HSV-2 infection.2 While the virus is highly contagious during outbreaks of visible sores, it can also be transmitted without any noticeable symptoms, a phenomenon known as asymptomatic shedding.3

HOW DO YOU TREAT INITIAL HSV INFECTION?

There is no cure for HSV infection. Antiviral medications such as acyclovir, valacyclovir, and famciclovir can mitigate the severity, frequency, and duration of outbreaks and lower the risk of transmission. It is crucial to start antivirals as soon as possible, ideally within 72 hours of symptom onset.4

The primary objective of antiviral medications is to reduce the duration and severity of the disease by days to weeks. Oral antiviral medications have been shown to decrease the severity of symptoms, reduce the duration of pain, accelerate lesion healing, and minimize viral shedding in patients experiencing their first episode of primary genital HSV infection.4 The US Centers for Disease Control and Prevention recommends 7 to 10 days of acyclovir 400 mg orally 3 times a day, famciclovir 250 mg orally 3 times a day, or valacyclovir 1,000 mg orally 2 times a day.5 The dose of these medications needs to be adjusted based on the patient’s creatinine clearance rate. Valacyclovir is an alternative to acyclovir, offering the advantage of more convenient administration with comparable efficacy.4 No randomized trial has compared the efficacy with famciclovir.

WHAT IS RECURRENT HSV?

HSV can lead to recurrent outbreaks. After the initial infection, HSV remains dormant in the sensory nerve ganglia and may reactivate under stress, illness, or immunosuppression, causing subsequent outbreaks. The frequency of these outbreaks may diminish over time.6 HSV-2 is associated with a higher rate of recurrence (a median of 4 times per year) than HSV-1 (with a median of once per year).7 The initial treatment does not reduce the frequency of these recurrences.8 Recurrent HSV can be managed with either episodic or chronic suppressive therapy.

HOW DO YOU DIFFERENTIATE HSV-1 AND HSV-2 INFECTION?

For patients with active genital lesions, type-specific virologic testing by culture or nucleic acid amplification should distinguish HSV-1 from HSV-2 lesions. In the absence of active genital lesions, serologic tests can help differentiate the cause of recurrent oral and genital lesions. However, because many asymptomatic people test positive for antibodies, serologic testing is not routinely indicated in the general population and should be used only to determine risk for a partner who may be discordant (ie, not previously positive for HSV-1 or HSV-2 on serologic testing).9

EPISODIC THERAPY VS CHRONIC SUPPRESSIVE THERAPY

Episodic treatment is self-administration of the medication at the first signs of prodromal symptoms such as tingling, paresthesia, and itching to prevent the onset of the outbreak (Table 1).5 Early administration of antivirals has been shown to be beneficial.4 Episodic therapy can shorten the time to crusting and healing of lesions and can also decrease viral shedding.10 Episodic regimens are typically shorter in duration than initial therapy and can vary from 1 day to 5 days. Patients with human immunodeficiency virus (HIV) infection should be treated for 5 days.

View this table:
  • View inline
  • View popup
TABLE 1

Episodic treatment regimens for recurrent herpes simplex virus infection

For HSV-2 infection, chronic suppressive therapy is preferred over episodic therapy, as it has been linked to greater treatment satisfaction and a decreased risk and frequency of recurrence.11 No data are available regarding its efficacy in preventing transmission among individuals with genital herpes caused by HSV-1. Because HSV-1 infection carries a lower rate of recurrent outbreaks than HSV-2, most patients with genital HSV-1 infection do not require suppressive therapy.1

WHICH PATIENTS BENEFIT MOST FROM CHRONIC SUPPRESSIVE THERAPY?

Unfortunately, the antiviral drugs used to treat the initial episode of HSV infection do not eradicate the latent virus, nor do they influence the risk, frequency, or severity of recurrences once the drug is discontinued. As a result, chronic suppressive therapy is recommended for patients with a history of genital HSV-2 infection who experience frequent or severe outbreaks.4 This recommendation also extends to patients with risk factors such as ongoing immunosuppression (solid-organ transplant, bone marrow transplant, HIV) and patients with a history of genital herpes who have multiple partners or partners who are discordant.12

Chronic suppressive therapy has been found to reduce the frequency of genital herpes recurrences by 70% to 80%.5,11,13 In addition to decreasing the severity of symptoms2 and reducing the frequency of outbreaks,13 suppressive therapy has been shown to reduce asymptomatic viral shedding, thereby decreasing the potential for transmission to HSV-uninfected sexual partners.3

Currently recommended agents for chronic suppressive therapy include acyclovir, valacyclovir, and famciclovir (Table 2).5 Once-daily treatment with valacyclovir 500 mg has been shown to decrease the rate of HSV-2 transmission in discordant heterosexual couples where 1 partner has a history of genital HSV-2 infection.14

View this table:
  • View inline
  • View popup
TABLE 2

Chronic suppressive regimens in patients without and with HIV infection

However, for HSV-2, the question remains whether reducing the frequency of recurrences equates to a lower risk of transmission to sexual partners. Kim et al15 found that the severity of HSV-2 infection defined as the frequency of recurrences did not help identify patients most likely to transmit the infection to a discordant partner.15 A higher daily dose of valacyclovir (1,000 mg) is recommended in patients who have 10 or more episodes per year.13 Higher doses are typically recommended for patients with HIV and in pregnant women to prevent neonatal herpes infections.5 Patients should be evaluated annually for continuation of chronic suppression.5

THE BOTTOM LINE

Chronic suppressive therapy is recommended for patients with recurrent genital HSV infection. It is effective in decreasing the frequency and severity of symptoms, and can decrease viral shedding and transmission from HSV-2-infected patients to sexual partners. HSV-1 is associated with a lower risk of recurrent infection.7 Current available data do not show a clear benefit of chronic suppressive therapy in patients with recurrent HSV-1 infection.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Wald A
    . Genital HSV-1 infections. Sex Transm Infect 2006; 82(3): 189–190. doi:10.1136/sti.2006.019935
    OpenUrlFREE Full Text
  2. ↵
    1. Gupta R,
    2. Warren T,
    3. Wald A
    . Genital herpes. Lancet 2007; 370(9605):2127–2137. doi:10.1016/S0140-6736(07)61908-4
    OpenUrlCrossRefPubMed
  3. ↵
    1. Whitley RJ,
    2. Hook EW 3rd.
    Shedding patterns of genital herpes simplex virus infections. JAMA 2022; 328(17):1710–1711. doi:10.1001/jama.2022.18930
    OpenUrlCrossRef
  4. ↵
    1. Cernik C,
    2. Gallina K,
    3. Brodell RT
    . The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008; 168(11):1137–1144. doi:10.1001/archinte.168.11.1137
    OpenUrlCrossRefPubMed
  5. ↵
    1. Workowski KA,
    2. Bachmann LH,
    3. Chan PA, et al
    . Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021; 70(4):1–187. doi:10.15585/mmwr.rr7004a1
    OpenUrlCrossRefPubMed
  6. ↵
    1. Benedetti JK,
    2. Zeh J,
    3. Corey L
    . Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999; 131(1):14–20. doi:10.7326/0003-4819-131-1-199907060-00004
    OpenUrlCrossRefPubMed
  7. ↵
    1. Holmes KK,
    2. Sparling PF,
    3. Stamm WE, et al.
    1.  Corey L,
    2. Wald A
    . Genital herpes. In: Holmes KK, Sparling PF, Stamm WE, et al., eds. Sexually Transmitted Diseases, 4th ed. New York, NY: McGraw-Hill; 2008:399–437.
  8. ↵
    1. Corey L,
    2. Mindel A,
    3. Fife KH,
    4. Sutherland S,
    5. Benedetti J,
    6. Adler MW
    . Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex Transm Dis 1985; 12(4):215–218. doi:10.1097/00007435-198510000-00009
    OpenUrlCrossRefPubMed
  9. ↵
    1. Feltner C,
    2. Grodensky C,
    3. Ebel C, et al
    . Serologic screening for genital herpes: an updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016; 316(23):2531–2543. doi:10.1001/jama.2016.17138
    OpenUrlCrossRef
  10. ↵
    1. Spruance SL,
    2. Stewart JC,
    3. Rowe NH,
    4. McKeough MB,
    5. Wenerstrom G,
    6. Freeman DJ
    . Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990; 161(2):185–190. doi:10.1093/infdis/161.2.185
    OpenUrlCrossRefPubMed
  11. ↵
    1. Romanowski B,
    2. Marina RB,
    3. Roberts JN; Valtrex HS230017 Study Group
    . Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003; 30(3):226–231. doi:10.1097/00007435-200303000-00010
    OpenUrlCrossRefPubMed
  12. ↵
    1. Gupta R,
    2. Wald A,
    3. Krantz E, et al
    . Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190(8):1374–1381. doi:10.1086/424519
    OpenUrlCrossRefPubMed
  13. ↵
    1. Reitano M,
    2. Tyring S,
    3. Lang W, et al
    . Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 1998; 178(3):603–610. doi:10.1086/515385
    OpenUrlCrossRefPubMed
  14. ↵
    1. Corey L,
    2. Wald A,
    3. Patel R, et al
    . Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350(1):11–20. doi:10.1056/NEJMoa035144
    OpenUrlCrossRefPubMed
  15. ↵
    1. Kim HN,
    2. Wald A,
    3. Harris J,
    4. Almekinder J,
    5. Heitman C,
    6. Corey L
    . Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Sex Transm Dis 2008; 35(2):124–128. doi:10.1097/OLQ.0b013e31815407d7
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (3)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 3
1 Mar 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is there a role for chronic suppressive therapy in herpes simplex virus infection?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is there a role for chronic suppressive therapy in herpes simplex virus infection?
Sandhya R. Nagarakanti, Ahmed M. Zikri
Cleveland Clinic Journal of Medicine Mar 2024, 91 (3) 151-153; DOI: 10.3949/ccjm.91a.23099

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Is there a role for chronic suppressive therapy in herpes simplex virus infection?
Sandhya R. Nagarakanti, Ahmed M. Zikri
Cleveland Clinic Journal of Medicine Mar 2024, 91 (3) 151-153; DOI: 10.3949/ccjm.91a.23099
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • WHAT IS HSV INFECTION?
    • HOW DO YOU TREAT INITIAL HSV INFECTION?
    • WHAT IS RECURRENT HSV?
    • HOW DO YOU DIFFERENTIATE HSV-1 AND HSV-2 INFECTION?
    • EPISODIC THERAPY VS CHRONIC SUPPRESSIVE THERAPY
    • WHICH PATIENTS BENEFIT MOST FROM CHRONIC SUPPRESSIVE THERAPY?
    • THE BOTTOM LINE
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Family Medicine
  • Infectious Diseases
  • Men's Health
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire